Fresh from $2.5B pact, BridgeBio, Helsinn expand collaboration to cover preclinical cancer prospectsnews2021-11-19T12:28:26+00:00November 19th, 2021|FierceBiotech|
Merck pauses ‘very important’ HIV program after seeing red flag in phase 2 trial of once-weekly combonews2021-11-19T10:04:43+00:00November 19th, 2021|FierceBiotech|
Personalized T cells could offer an immunotherapy option to children with brain tumorsnews2021-11-18T18:54:28+00:00November 18th, 2021|FierceBiotech|
Data manipulation expert Elisabeth Bik compares the tales of 2 accused biotechs: Cassava and Athiranews2021-11-18T18:50:19+00:00November 18th, 2021|FierceBiotech|
J&J previews $60B-a-year future with plans to go after viruses that have long evaded vaccine makersnews2021-11-18T17:26:45+00:00November 18th, 2021|FierceBiotech|
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna news2021-11-18T13:24:28+00:00November 18th, 2021|FierceBiotech|
Gilead hits go on a host of Arcus cancer programs but forgoes rumored buyout in a $725M pact as TIGIT leads the waynews2021-11-18T12:50:05+00:00November 18th, 2021|FierceBiotech|
With FDA scrutinizing its data, AstraZeneca shows durability of COVID-preventing antibodiesnews2021-11-18T11:31:18+00:00November 18th, 2021|FierceBiotech|
Psychedelic psilocybin cuts cravings and boosts key brain functions in rat models of alcohol use disordernews2021-11-17T20:53:05+00:00November 17th, 2021|FierceBiotech|
Valo whacks SPAC merger, blaming ‘market conditions’ for end of $750M Khosla deal news2021-11-17T13:53:02+00:00November 17th, 2021|FierceBiotech|
